2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.
Sarah Sammons, MD, assistant professor of medicine, Department of Medicine, Duke University School of Medicine, member, Duke Cancer Institute, Duke Health, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial (NCT03529110) in HER2-positive breast cancer.
The topline results of the randomized DESTINY-Breast03 trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS) with fam-trastuzumab deruxtecan-nxki (Enhertu) vs ado-trastuzumab emtansine (T-DM1; Kadcyla) in patients with HER2-positive metastatic breast cancer. By blinded-independent review, the median PFS was not reached with trastuzumab deruxtecan vs 6.8 months with T-DM1. By investigator assessment, the median PFS was 25.1 months vs 7.2 months, respectively.
Although the overall survival data were immature at the time of the data presentation, the data represent a paradigm shift in the second-line setting for patients with HER2-positive breast cancer, Sammons explains.
Additionally, patients with brain metastases had a median PFS of 15 months with trastuzumab deruxtecan vs 5.7 months with T-DM1. As such, trastuzumab deruxtecan should be considered a standard second-line option for patients with stable brain metastases, Sammons concludes.